DRIVERS OF PROGRESSION
- Elevated blood glucose (A1c) levels
- Elevated blood pressure (BP)
- High intraglomerular pressure
Inflammatory and Fibrotic Drivers
- Presence and/or release of proinflammatory cytokines and fibrotic proteins
Chronic kidney disease (CKD) progression
CKD: chronic kidney disease; T2D: type 2 diabetes.
Inflammatory and fibrotic drivers in the kidneys are largely unaddressed in patients with CKD in T2D1
Today, physicians are fighting CKD in T2D on multiple fronts. But even with well-controlled A1c and blood pressure (BP), many patients with CKD in T2D are still experiencing CKD progression. While modest gains have been made due to advancements in the field, there are more opportunities to reduce the residual risk of4-7:
- End-stage kidney disease (ESKD)
- Death from renal disease
- Alicic RZ, Rooney MT, Tuttle KR. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
- Bauersachs J, Jaisser F, Toto R. Hypertension. 2015;65(2):257-263.
- ACCORD Study Group, Cushman WC, Evans GW, et al. N Engl J Med. 2010;362(17):1575-1585.
- Duckworth W, Abraira C, Moritz T, et al. N Engl J Med. 2009;360(2):129-139.
- Ismail-Beigi F, Craven T, Banerji MA, et al. Lancet. 2010;376(9739):419-430.
- Brenner BM, Cooper ME, De Zeeuw D, et al. N Engl J Med. 2001;345(12):861-869.
- Thomas MC, Brownlee M, Susztak K, et al. Nat Rev Dis Primers. 2015;1:15018.